Paul  Sauer net worth and biography

Paul Sauer Biography and Net Worth

SVP of Vaxcyte
Paul has over 30 years of experience industrializing biologics for numerous biotechnology companies. Prior to joining Vaxcyte, Paul was VP of Process Sciences & Manufacturing at Igenica Biotherapeutics, where he initiated the company’s development activities and built its supply chain network for GMP manufacturing of its antibody drug conjugates. Prior to that, Paul was Senior Director of Process Development at OncoMed Pharmaceuticals, where he contributed to multiple IND filings for the company’s antibody-based oncology therapies. He also held various process, engineering, scale-up, and manufacturing positions at Protein Design Labs, Scios, and Genentech. Through the years, Paul has contributed to numerous approved biologics, including Genentech’s Activase® and Pulmozyme®. He also contributed significantly to the development of the patented high-yield process that formed the basis for production of Abbvie and Biogen’s ZinbrytaTM, a humanized antibody approved for the treatment of Multiple Sclerosis. Paul earned an MBA at Santa Clara University and a BS in Genetics from the University of California, Davis. Paul enjoys spending quality time with his family and helping his wife with her non-profit organization focused on transforming health through diet.

What is Paul Sauer's net worth?

The estimated net worth of Paul Sauer is at least $1.27 million as of August 22nd, 2022. Mr. Sauer owns 14,687 shares of Vaxcyte stock worth more than $1,270,866 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Sauer may own. Additionally, Mr. Sauer receives an annual salary of $608,960.00 as SVP at Vaxcyte. Learn More about Paul Sauer's net worth.

How old is Paul Sauer?

Mr. Sauer is currently 63 years old. There are 7 older executives and no younger executives at Vaxcyte. Learn More on Paul Sauer's age.

What is Paul Sauer's salary?

As the SVP of Vaxcyte, Inc., Mr. Sauer earns $608,960.00 per year. There are 3 executives that earn more than Mr. Sauer. The highest earning executive at Vaxcyte is Mr. Grant E. Pickering M.B.A., Co-Founder, CEO & Director, who commands a salary of $1,130,000.00 per year. Learn More on Paul Sauer's salary.

How do I contact Paul Sauer?

The corporate mailing address for Mr. Sauer and other Vaxcyte executives is 353 HATCH DRIVE, FOSTER CITY CA, 94404. Vaxcyte can also be reached via phone at 650-837-0111 and via email at [email protected]. Learn More on Paul Sauer's contact information.

Has Paul Sauer been buying or selling shares of Vaxcyte?

Paul Sauer has not been actively trading shares of Vaxcyte in the last ninety days. Most recently, Paul Sauer sold 3,000 shares of the business's stock in a transaction on Monday, August 22nd. The shares were sold at an average price of $25.93, for a transaction totalling $77,790.00. Following the completion of the sale, the senior vice president now directly owns 14,687 shares of the company's stock, valued at $380,833.91. Learn More on Paul Sauer's trading history.

Who are Vaxcyte's active insiders?

Vaxcyte's insider roster includes Elvia Cowan (SVP), Mikhail Eydelman (SVP), Jeff Fairman (VP), Halley Gilbert (Director), Andrew Guggenhime (CFO), Heath Lukatch (Director), Grant Pickering (CEO), Paul Sauer (SVP), James Wassil (COO), Jim Wassil (COO), and Jane Wright-Mitchell (General Counsel). Learn More on Vaxcyte's active insiders.

Are insiders buying or selling shares of Vaxcyte?

In the last year, insiders at the sold shares 49 times. They sold a total of 427,456 shares worth more than $35,141,433.71. The most recent insider tranaction occured on December, 18th when CFO Andrew Guggenhime sold 8,000 shares worth more than $710,240.00. Insiders at Vaxcyte own 3.1% of the company. Learn More about insider trades at Vaxcyte.

Information on this page was last updated on 12/18/2024.

Paul Sauer Insider Trading History at Vaxcyte

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/22/2022Sell3,000$25.93$77,790.0014,687View SEC Filing Icon  
7/27/2022Sell3,000$25.00$75,000.0017,687View SEC Filing Icon  
7/20/2022Sell3,000$25.00$75,000.0020,687View SEC Filing Icon  
5/23/2022Sell3,000$26.22$78,660.0023,687View SEC Filing Icon  
4/22/2022Sell3,000$25.00$75,000.0025,125View SEC Filing Icon  
3/22/2022Sell3,000$25.00$75,000.00View SEC Filing Icon  
3/10/2022Sell6,000$25.00$150,000.00View SEC Filing Icon  
12/29/2021Sell6,000$25.00$150,000.00View SEC Filing Icon  
9/22/2021Sell5,307$25.20$133,736.40View SEC Filing Icon  
2/11/2021Sell2,500$26.65$66,625.0080,399View SEC Filing Icon  
1/11/2021Sell2,500$26.21$65,525.00View SEC Filing Icon  
See Full Table

Paul Sauer Buying and Selling Activity at Vaxcyte

This chart shows Paul Sauer's buying and selling at Vaxcyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Vaxcyte Company Overview

Vaxcyte logo
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $86.53
Low: $86.25
High: $88.90

50 Day Range

MA: $98.70
Low: $85.75
High: $117.93

2 Week Range

Now: $86.53
Low: $53.83
High: $121.06

Volume

3,859,357 shs

Average Volume

922,601 shs

Market Capitalization

$10.78 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94